These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 16118804)

  • 1. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
    Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
    Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postchemoradiotherapy positron emission tomography predicts pathologic response and survival in patients with esophageal cancer.
    Jayachandran P; Pai RK; Quon A; Graves E; Krakow TE; La T; Loo BW; Koong AC; Chang DT
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):471-7. PubMed ID: 22381904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.
    Javeri H; Xiao L; Rohren E; Lee JH; Liao Z; Hofstetter W; Maru D; Bhutani MS; Swisher SG; Macapinlac H; Wang X; Ajani JA
    Cancer; 2009 Nov; 115(22):5184-92. PubMed ID: 19685531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy.
    Suzuki A; Xiao L; Hayashi Y; Macapinlac HA; Welsh J; Lin SH; Lee JH; Bhutani MS; Maru DM; Hofstetter WL; Swisher SG; Ajani JA
    Cancer; 2011 Nov; 117(21):4823-33. PubMed ID: 21456015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
    Port JL; Lee PC; Korst RJ; Liss Y; Meherally D; Christos P; Mazumdar M; Altorki NK
    Ann Thorac Surg; 2007 Aug; 84(2):393-400; discussion 400. PubMed ID: 17643605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of PET-CT in predicting survival in patients with esophageal cancer.
    Brown C; Howes B; Jamieson GG; Bartholomeusz D; Zingg U; Sullivan TR; Thompson SK
    World J Surg; 2012 May; 36(5):1089-1095. PubMed ID: 22374537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
    Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
    Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical application of (18)F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer.
    Kato H; Nakajima M; Sohda M; Tanaka N; Inose T; Miyazaki T; Fukuchi M; Oriuchi N; Endo K; Kuwano H
    Cancer; 2009 Jul; 115(14):3196-203. PubMed ID: 19472406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer.
    Griffin JM; Reed CE; Denlinger CE
    Ann Thorac Surg; 2012 Jun; 93(6):1855-9; discussion 1860. PubMed ID: 22516835
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
    J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment.
    Wieder HA; Brücher BL; Zimmermann F; Becker K; Lordick F; Beer A; Schwaiger M; Fink U; Siewert JR; Stein HJ; Weber WA
    J Clin Oncol; 2004 Mar; 22(5):900-8. PubMed ID: 14990646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.